Literature DB >> 9302689

The Li-Fraumeni syndrome: an inherited susceptibility to cancer.

S C Evans1, G Lozano.   

Abstract

The Li-Fraumeni syndrome is a rare autosomal-dominant disease whose hallmark is a predisposition to a wide range of cancers among members of a family. Many of these families have a germline mutation within the tumor suppressor gene TP53, which encodes the p53 protein. The inheritance of a mutant TP53 allele results in a 25-fold increase in the chance of developing cancer by 50 years of age, compared with the general population. TP53 mutations are also very common in the development of somatic tumors. This article reviews the biological and biochemical role of p53 in the susceptibility to cancer in Li-Fraumeni syndrome.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9302689     DOI: 10.1016/S1357-4310(97)01105-2

Source DB:  PubMed          Journal:  Mol Med Today        ISSN: 1357-4310


  9 in total

1.  Hypophosphorylation of Mdm2 augments p53 stability.

Authors:  Christine Blattner; Trevor Hay; David W Meek; David P Lane
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

2.  The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube.

Authors:  Wa Xian; Alexander Miron; Michael Roh; Dana R Semmel; Yosuf Yassin; Judy Garber; Esther Oliva; Annekathryn Goodman; Karishma Mehra; Ross S Berkowitz; Christopher P Crum; Bradley J Quade
Journal:  J Pathol       Date:  2010-01       Impact factor: 7.996

Review 3.  Contribution of p53 to metastasis.

Authors:  Emily Powell; David Piwnica-Worms; Helen Piwnica-Worms
Journal:  Cancer Discov       Date:  2014-03-21       Impact factor: 39.397

4.  Oncogenes do not Fully Override Cell-intrinsic Traits: Pronounced Impact of the Cellular Programme.

Authors:  Józefa Węsierska-Gądek; Eva Walzi; Iva Dolečkova; Gerald Schmid
Journal:  Cancer Microenviron       Date:  2009-09-04

5.  A novel genetic modifier of p53, mop1, results in embryonic lethality.

Authors:  Susan C Evans; Min Liang; Christopher Amos; Xiangjun Gu; Guillermina Lozano
Journal:  Mamm Genome       Date:  2004-06       Impact factor: 2.957

6.  Mammary tumor modifiers in BALB/cJ mice heterozygous for p53.

Authors:  Joanna G Koch; Xiangjun Gu; Younghun Han; Adel K El-Naggar; Melissa V Olson; Daniel Medina; D Joseph Jerry; Anneke C Blackburn; Gary Peltz; Christopher I Amos; Guillermina Lozano
Journal:  Mamm Genome       Date:  2007-06-08       Impact factor: 2.957

7.  Regular surveillance for Li-Fraumeni Syndrome: advice, adherence and perceived benefits.

Authors:  C R M Lammens; E M A Bleiker; N K Aaronson; A Wagner; R H Sijmons; M G E M Ausems; A H J T Vriends; M W G Ruijs; T A M van Os; L Spruijt; E B Gómez García; A Cats; T Nagtegaal; S Verhoef
Journal:  Fam Cancer       Date:  2010-12       Impact factor: 2.375

8.  p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.

Authors:  Lindi Chen; Deborah A Tweddle
Journal:  Front Oncol       Date:  2012-11-28       Impact factor: 6.244

Review 9.  Polo-like kinase-1 in DNA damage response.

Authors:  Sun-Yi Hyun; Hyo-In Hwang; Hyo-In Hwan; Young-Joo Jang
Journal:  BMB Rep       Date:  2014-05       Impact factor: 4.778

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.